The wide heterogeneity in the use of first line treatment for migraine across headache centres globally shows the need for better evidence to inform guidance, researchers say. A study of 600 patients from seven countries including Australia found the most commonly used acute drugs were triptans (70.3%) especially sumatriptan, followed by NSAIDs (63.3%). Triptans were ...
Choice of first line migraine medication shows wide variation
By Mardi Chapman
27 May 2021